Exhibit 99.1
University of British Columbia to Perform Clinical Study on
the Cardiovascular and
Cognitive Health Effects of Lexarias
TurboCBDTM.
Kelowna, British Columbia August 31, 2017 Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the Company or Lexaria) announces the worlds first clinical study on human volunteers of cannabindiol (CBD) within Lexarias high absorption TurboCBD product, to evaluate its effects on both cardiovascular health and cognitive function.
The study will have a double-blind and placebo controlled cross-over design measuring effects both after a single dose, and also after 7 days of daily dosing in 24 volunteers. The study hypothesises that, following TurboCBD supplementation, circulating CBD and nitric oxide will increase in both young and old participants; that glucose and blood pressure will remain stable; and that vascular function, and cognitive and physical exercise performance will improve to a greater extent in older participants. This research study has been approved by the Clinical Research Ethics Board at the University of British Columbia (UBC).
Professor Philip Ainslie, PhD, Co-Director of the Centre for Heart, Lung and Vascular Health, UBC Okanagan Campus, Kelowna, Canada, will be Principal Investigator of a team of co-investigators. UBC has consistently been ranked one of the top three universities in Canada, has over 62,000 students on two campuses, and is further considered one of the top research universities in the world. UBC has conducted several earlier studies in the cannabis sector, available for review at https://news.ubc.ca/tag/marijuana/
This advanced study will utilize the latest clinical evaluation techniques to provide pharma-level pharmacokinetic and pharmacodynamic performance data of TurboCBD, including blood sampling, physiological measures, cognitive function testing, vascular function testing, and exercise performance testing. Outcome measurements will include circulating CBD and nitric oxide markers, plasma glucose, plasma insulin, blood pressure, heart rate, respiration, peripheral and brain blood flow and a battery of neuropsychological performance tests.
Dr. Philip Ainslie comments that, This study gives us a great opportunity to obtain world class clinical data on the health and performance benefits of cannabidiol using Lexarias unique high absorption TurboCBD capsules in our state of the art laboratories. It is very exciting to be one of the first if not the first to conduct these kinds of studies in Canada. The potential implications of the study are far-reaching: from understanding the fundamental biological mechanism(s) of high absorption CBD in humans, to how this might influence blood vessel physiology and human performance. To quantify the pharmacokinetics of TurboCBD will allow us to make informed recommendations of optimum dosing in order to improve vascular health and performance throughout healthy aging. Once we understand these processes better, the applications to various clinical populations can then be explored. There are also many other CBD products from Lexaria that could also be explored in due course the partnership with academia and Lexaria Biosciences is an excellent means to develop new collaborative ideas, products and positively impact society.
Lexaria is proud to be advancing our collective knowledge of the benefits of CBD specifically showcasing the benefits of Lexarias unique patented delivery technology, said Chris Bunka, CEO of Lexaria Bioscience. Results will advance Lexarias ability to custom design products that increase the leading performance our technology already offers to customers.
Additional information will be released upon completion and interpretation of test results.
About Lexaria
Lexaria Bioscience Corp. has developed
and out-licenses its disruptive technology that promotes healthier ingestion
methods, lower overall dosing and higher effectiveness of lipophilic active
molecules. Lexaria has multiple patents pending in over 40 countries around the
world and was granted its first patents in the USA and in Australia related to
edible forms of cannabinoids. Lexarias technology provides increases in
intestinal absorption rates; more rapid delivery to the bloodstream; and
important taste-masking benefits, for orally administered bioactive molecules
including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules.
www.lexariabioscience.com
For regular updates, connect with Lexaria on Facebook (https://www.facebook.com/Lexaria-
Corp-106280556370600/) and Twitter (https://twitter.com/lexariacorp)
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience
Corp.
Alex Blanchard, Communications Manager
(778) 796-1897
Or
NetworkNewsWire (NNW)
www.NetworkNewsWire.com
FORWARD-LOOKING STATEMENTS
This release includes
forward-looking statements. Statements which are not historical facts are
forward-looking statements. The Company makes forward-looking public statements
concerning its expected future financial position, results of operations, cash
flows, financing plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management for future
operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"
"will," and other similar expressions are forward-looking statements, including
but not limited to: that any additional stock warrants or stock options will be
exercised. Such forward-looking statements are estimates reflecting the
Company's best judgment based upon current information and involve a number of
risks and uncertainties, and there can be no assurance that other factors will
not affect the accuracy of such forward-looking statements. Factors which could
cause actual results to differ materially from those estimated by the Company
include, but are not limited to, government regulation, managing and maintaining
growth, the effect of adverse publicity, litigation, competition, the patent
application and approval process and other factors which may be identified from
time to time in the Company's public announcements and filings. There is no
assurance that existing capital is sufficient for the Company's needs or that it
will be able to raise additional capital. There is no assurance that Lexaria
will successfully complete any other contemplated or existing technology license
agreements; or that results from any studies will be favorable or in any way
support future business activities of any kind. There is no assurance that any
planned corporate activity, business venture, or initiative will be pursued, or
if pursued, will be successful. There is no assurance that any of Lexarias
postulated uses, benefits, or advantages for the patented and patent-pending
technology will in fact be realized in any manner or in any part. No statement
herein has been evaluated by the Food and Drug Administration (FDA). Lexaria
Energy Foods, Ambarii, and ViPovaTM products are not intended to
diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.